

Notice of Allowability	Application No.	Applicant(s)	
	10/560,281	TACHIBANA ET AL.	
	Examiner	Art Unit	
	Karen Cheng	1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to amendments filed 04/23/07.
2. The allowed claim(s) is/are 1-5, 7, 11-17, now renumbered 1-13.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

DETAILED ACTION

Claims 1-17 are currently pending in the instant application. Claims 6 and 8-10 have been cancelled by applicant. The non-cancelled claims have been renumbered as claims 1-13.

Response to Amendments

Applicant's amendments found in Amendment – After Non-Final Rejection, filed 04/23/2007, have been fully considered and are entered. The claim objections of claims 6 and 8 have been withdrawn in view of applicant's cancellation of the claims. The rejections of claim 10 under 35 USC 101 and 35 USC 112, 2nd paragraph have been withdrawn in view of applicant's cancellation of the claim. The enablement rejections under 35 USC 112, first paragraph of claims 8 and 9 have been withdrawn in view of applicant's cancellation of the claims.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.


The application has been amended as follows:

1. Delete from **Claim 1** the phrase "[Formula 1]".
2. Delete from **Claim 11** the phrases "[Formula 2]", "[Formula 3]", "[Formula 4]".
3. Delete from **Claim 12** the phrase "[Formula 5]".
4. Delete from **Claim 13** the phrase "[Formula 6]".


Statement of Reasons for Allowance

The following is an examiner's statement of reasons for allowance.


This invention relates to a process of preparation and compounds, salts, prodrugs, solvates, pharmaceutical compositions of the

formula  wherein n is 1 to 20, R¹ and R² are as defined as

well as the compounds of formula



and

 Rb. The novel and non-obvious aspect of this invention is the imidazolidine ring containing an aminosulfonylalkyl substituent. The closest prior art of record, EP 0580459, discloses compounds that have an aryl sulfonylalkyl [-(CH₂)_nSO₂-Ar] substituent but fails to teach or suggest the aminosulfonylalkyl substituent of applicant's instantly claimed compound(s) and pharmaceutical composition.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cheng whose telephone number is 571-272-6233. The examiner can normally be reached on M-F, 9AM to 5:30PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Karen Cheng

Karen Cheng
Patent Examiner, AU 1626
10 May 2007

REBECCA ANDERSON
PATENT EXAMINER


For Joseph McKane
Supervisory Patent Examiner, AU 1626